Pipeline Insight: Non-insulin Antidiabetics - Three New Classes Compete for Market Control

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2004-12-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Despite the presence of well tried and liked compounds for the treatment of diabetes, such as insulin, metformin and sulfonylureas and the recent introduction of new classes such as TZDs, AGIs and PGRs, there are still important unmet needs in the treatment of diabetes. As a result, a great surge of activity towards the discovery and development of new agents has been recently noted.


Scope

  • Evaluation of patient potential for developmental antidiabetics over the period 2004-2012
  • Scrutiny of key impacts on the R&D approach and cost, evaluation of optimal clinical trial end points and identification of suitable comparators.
  • Evaluation of key players in the antidiabetics market and opposing company approaches to development and commercialization
  • Analysis of key antidiabetic drugs in development and their ability to satisfy major unmet needs and compete with existing agents


    • Report Highlights
    One of the most exciting classes of agents in development is GLP-1 agonists. There have been suggestions that these agents will exhibit efficacy over an extended period of time and that they will offer some effect on beta-cell preservation. However, these findings need to be conclusively proven through specifically designed trials.

    DPPIV inhibitors are expected to enter the market in the following years. Their main advantage is their mode of administration. They will be available as pills or capsules, contrary to GLP-1 agonists that will be injectable. This makes them far more attractive and is likely to help their faster uptake and increased patient compliance.

    Dual PPAR agonists were once hailed as the next big development in the diabetes treatment. However the recent withdrawal of many leading agents following safety concerns has prompted the FDA to request additional safety data before considering the approval of such compounds. This development will severely delay the progress of dual PPAR analogs.


    Reasons to Purchase

  • View independent forecasts of sales in late stage development for treatment of diabetes in novel classes
  • Understand physicians' views on incretin mimetics as the potential next big development in the diabetes treatment
  • Identify early stage antidiabetic compounds with high potential being developed by companies seeking a marketing partner

    • Table of Contents

    Other users found this report page using the following search terms: diabetes antidiabetics diabetes agonists glp1 pipeline ppar new clinical trials market

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.